Reports

Thomas Brenzikofer

Thomas Brenzikofer

Manager Network and Events, Healthcare Innovation - DayOne


Tel. +41 61 295 50 16

thomas.notexisting@nodomain.combrenzikofer@baselarea.notexisting@nodomain.comswiss
report ICT
big data (img: kentoh/shutterstock)

big data (img: kentoh/shutterstock)

19.07.2017

Merck uses Genedata software for innovation

Pharmaceutical company Merck is using the Genedata Biologics platform developed by Genedata to scale-up their bispecific antibody research. The aim is to develop innovative therapeutics for oncology, immunology and neurodegenerative diseases.

The Basel-based company Genedata develops software for scientific applications. One of these is the Genedata Biologics system, which can be used to research bispecific antibodies that are able to identify two different antigens.

According to a press release, Genedata first released this platform in 2011. Merck began using it in 2015 and has since expanded application to encompass ever more areas. The pharma company is now planning to scale-up its bispecific discovery programmes with Genedata Biologics. This research area involves the need to evaluate large panels of bispecific antibodies. Genedata’s software substantially enhances throughput volumes. Merck uses this research to develop therapeutics for oncology, immunology and neurodegenerative diseases.

“We are delighted to see Merck expand the application scope of Genedata Biologics to their innovative bispecific research and development programmes,” commented Dr Othmar Pfannes, CEO of Genedata. He also said that the company intends to further expand the platform in close collaboration with its growing customer base to support new technologies, which will include cell and gene therapies.

Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok